Abstract
The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB . The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112: 504–510.
Gonsalves A, Carrier M, Wells PS, McDiarmid SA, Huebsch LB, Allan DS . Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 6: 1468–1473.
Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903–908.
LeBlanc R, Roy J, Demers C, Vu L, Cantin G . A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991–996.
Alegre A, Requena MJ, Fernandez-Villalta MJ, Orts M, Gilsanz F, Tomas JF et al. Quinton-Mahurkar catheter as short-term central venous access for PBSC collection: single-center experience of 370 aphereses in 110 patients. Bone Marrow Transplant 1996; 18: 865–869.
Saif MW, Leitman SF, Cusack G, Horne M, Freifeld A, Venzon D et al. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. Ann Oncol 2004; 15: 1366–1372.
Stephens LC, Haire WD, Tarantolo S, Reed E, Schmit-Pokorny K, Kessinger A et al. Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC). Transfus Sci 1997; 18: 187–193.
Warkentin TE, Greinacher A, Koster A, Lincoff AM . Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S–380S.
Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065–1071.
Kuroiwa M, Okamura T, Kanaji T, Okamura S, Harada M, Niho Y . Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. Int J Hematol 1996; 63: 311–316.
Carrier M, Tay J, Fergusson D, Wells PS . Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5: 2552–2554.
Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009; 373: 567–574.
Hong AP, Cook DJ, Sigouin CS, Warkentin TE . Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101: 3049–3051.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Naina, H., Pruthi, R., Inwards, D. et al. Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. Bone Marrow Transplant 46, 291–293 (2011). https://doi.org/10.1038/bmt.2010.106
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.106
Keywords
This article is cited by
-
Bone marrow-derived cell mobilization by G-CSF to enhance osseointegration of bone substitute in high tibial osteotomy
Knee Surgery, Sports Traumatology, Arthroscopy (2013)